The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19
1 other identifier
interventional
60
1 country
1
Brief Summary
There are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Unfortunately, the scientific community has little knowledge of the molecular details of SARS-CoV-2 infection. The drugs we are chosen are used as clinical trials for antiviral and there is no proven guide for specificity and effectiveness against the virus so the results are different Now the clinical trials and research authorities are work speedily to target the most proven treatment for the virus so anything is infantile until now. the covid-19 with time be more explained by scientists it is steroid response disease and cause thromosis and cytokine storm , the aim of the study to inhibit viral replication and decrease the severity of the disease as antiviral and anticytokine storm , antithrombosis Zinc is a mineral element needed to regulate adaptive immune cells' functions. Higher level of intracellular zinc showed to increase intracellular pH; which affect on RNA-dependent RNA polymerase and decrease replication mechanism of RNA viruses. Therefore, drugs that described as zinc ionophores could be used with zinc supplement to act as antiviral against many RNA viruses including SARS-CoV-2 Quercetin is natural compound act as zinc ionophore to cause zinc influx intracellular. Quercetin is a safe natural anti-oxidant and anti-inflammatory polyphenolic compound that found in various natural sources include onion, red grapes, honey and citrus fruits. It was shown that quercetin has the ability to chelate zinc ions and act as zinc ionophore. Therefore, quercetin could have antiviral activity against many RNA viruses . Quercetin, a flavonoid found in fruits and vegetables, has unique biological properties that may improve mental/physical performance and reduce infection risk ; These properties form the basis for potential benefits to overall health and disease resistance, including anti-carcinogenic, anti-inflammatory, antiviral, antioxidant, and psychostimulant activities, as well as the ability to inhibit lipid peroxidation, platelet aggregation and capillary permeability, and to stimulate mitochondrial biogenesis .There are various studies that report the immunomodulatory effect of bromelain . Bromelain activates natural killer cells and augments the production of granulocyte-macrophage-colony stimulating factor, IL-2, IL-6 and decreases the activation of Thelper cells. Thus, bromelain decreases the majority of inflammatory mediators and has demonstrated a significant role as an anti-inflammatory agent in various conditions Vitamin C is known as an essential anti-oxidant.,and enzymatic co-factor for physiological reactions such as hormone production, collagen synthesis and immune potentiation . Naturally, an insufficiency of vitamin C leads to severe injuries to multiple organs, especially to the heart and brain, since they are both highly aerobic organs that produce more oxygen radicals. In fact, studies of in vivo effect on vitamin C are difficult since most animals, except human and some primate, are capable of synthesizing vitamin C endogenously
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4 covid19
Started Jun 2020
Shorter than P25 for phase_4 covid19
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 20, 2020
CompletedFirst Submitted
Initial submission to the registry
July 5, 2020
CompletedFirst Posted
Study publicly available on registry
July 13, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 20, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
July 30, 2020
CompletedJuly 13, 2020
July 1, 2020
1 month
July 5, 2020
July 9, 2020
Conditions
Outcome Measures
Primary Outcomes (2)
days of stay at hospital after treatment and discharge
speed the days of recovery and discharge from hospital
28 days
serum zinc before and after treatment
the level of serum zinc is very important especially at chronic diseases
5-10 days
Secondary Outcomes (2)
questionnaire including parameters like BMI,,smoking , underling diseases, immunological treatment ,
28 days
day of negative conversion for nasopharyngeal swab for rt-PCR FOR covid-19
28 days
Study Arms (1)
Quercetin
EXPERIMENTALQuercetin 500 g of quercetin Quercetin will be administered orally once daily, in the morning before breakfast for 5-10 days or patient improves or discharged
Interventions
Dietary Supplement: Quercetin Treatment a daily dose of quercetin (500 mg) will be taken orally by proven COVID-19 cases intervention
Dietary Supplement:Bromealin Treatment a daily dose of bromelain(500 mg) will be taken orally by proven COVID-19 cases intervention
zinc 50 mg orally daily dose will be taken orally by proven COVID-19 cases intervention
Eligibility Criteria
You may qualify if:
- Age ≥ 18 years
- positive confirmed PCR covid-19
- moderate to severe cases
- obtained consent
- must be able to swallow tablets
You may not qualify if:
- Patients who live outside Saudia Arabia
- Pregnant women: Current known pregnancy positive pregnancy test.
- Lactating women.
- Documented allergy to pineapple or to quercetin
- Documented history of mental illnesses
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ministry of health.First health cluster ,Riaydh
Riyadh, Saudi Arabia
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Hiba Hamadelnil elsaeed
Netherlands: Ministry of Health, Welfare and Sports
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- director of mobile team tuberculosis ghubera, tuberculosis control program
Study Record Dates
First Submitted
July 5, 2020
First Posted
July 13, 2020
Study Start
June 20, 2020
Primary Completion
July 20, 2020
Study Completion
July 30, 2020
Last Updated
July 13, 2020
Record last verified: 2020-07